

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

ANNOUNCEMENT ON RECEIPT OF DRUG REGISTRATION CERTIFICATES BY XINXIN PHARMACEUTICAL PLANT (新新制药厂) OF THE COMPANY

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. INTRODUCTION

The Board wishes to announce that Xinxin Pharmaceutical Plant (新新制药厂), a branch of the Company, has recently received two (2) Drug Registration Certificates (《药品注册证书》) (the “**Drug Registration Certificates**”) approved and issued by the National Medical Products Administration of the People's Republic of China (国家药品监督管理局) in respect of Loxoprofen Sodium Patches (洛索洛芬钠贴剂) (the “**Drug**”). The key details of the Drug Registration Certificates and other relevant information relating to the Drug are set out in **Appendix A** to this announcement.

2. IMPACT ON THE COMPANY

The Company places great emphasis on pharmaceutical research and development (“**R&D**”) and exercises strict quality and safety controls throughout the R&D, production and sale of pharmaceutical products. The Drug was submitted for registration as a Category 4 chemical drug. Upon approval, the Drug is deemed to have passed the quality and efficacy consistency evaluation. The approval for registration of the Drug, which signifies that it meets the relevant requirements for drug registration, is not expected to have a material impact on the Company's short-term financial performance.

3. CAUTION IN TRADING

There may be uncertainties during the period from the marketing approval of the Drug to the commencement of its production and sale. Factors such as national policies and market conditions may affect the scale of future production and sales of the Drug.

Shareholders and potential investors are advised to exercise caution when trading in the shares of the Company.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
9 October 2026

APPENDIX A

1. Key Details of the Drug Registration Certificates

一、药品注册证书的主要内容

The two Drug Registration Certificates relate to the two specifications of the Drug set out below. As the other key details of the two Drug Registration Certificates are substantially the same, the relevant information is presented together in the table below, with the certificate-specific details separately identified.

Drug Name 药品名称	: Loxoprofen Sodium Patches 洛索洛芬钠贴剂
Dosage Form 剂型	: Patch 贴剂
Specification 规格	: (1) 14 cm × 10 cm, containing 100 mg of loxoprofen sodium (calculated as C ₁₅ H ₁₇ NaO ₃) 14cm×10cm, 含洛索洛芬钠 100mg (按 C ₁₅ H ₁₇ NaO ₃ 计) (2) 7 cm × 10 cm, containing 50 mg of loxoprofen sodium (calculated as C ₁₅ H ₁₇ NaO ₃) 7cm×10cm, 含洛索洛芬钠 50mg (按 C ₁₅ H ₁₇ NaO ₃ 计)
Registration Classification 注册分类	: Class 4 Chemical Drug 化学药品 4 类
Application Numbers 受理号	: (1) CYHS2501955 (2) CYHS2501956
Certificate Numbers 证书编号	: (1) 2026S03661 (2) 2026S03662
Marketing Authorisation Holder 上市许可持有人	: Xinxin Pharmaceutical Plant of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited 津药达仁堂集团股份有限公司新新制药厂
Manufacturer 生产企业	: Hunan Pagran Pharmaceutical Co., Ltd. 湖南派格兰药业有限公司
Drug Registration Standard Number 药品注册标准编号	: YBH28462026
Application Type 申请事项	: Drug Registration (Domestic Manufacture) 药品注册 (境内生产)

Drug Approval Numbers : (1) National Medical Products Administration Approval Nos.
药品批准文号 (known as “Guo Yao Zhun Zi” in Chinese regulatory terminology) H20266172
国药准字 H20266172

(2) National Medical Products Administration Approval Nos.
(known as “Guo Yao Zhun Zi” in Chinese regulatory terminology) H20266173
国药准字 H20266173

Validity Period of the : Until 28 September 2031
Drug Approval Numbers 至 2031 年 9 月 28 日
药品批准文号有效期

Approval Conclusion : Pursuant to the applicable laws and regulations, including the
审批结论 *Drug Administration Law of the People’s Republic of China* (《中华人民共和国药品管理法》), and upon review, this drug meets the relevant requirements for drug registration. Its registration is hereby approved and a Drug Registration Certificate is issued. The quality standards, package insert, labeling and manufacturing process shall be implemented in accordance with the approved versions attached to this certificate. The drug manufacturer may only commence production and sale upon compliance with the requirements of Good Manufacturing Practice (GMP).
根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。

2. Other Relevant Information on the Drug

二、药品的其他相关情况

The Drug (i.e. Loxoprofen Sodium Patches) utilises a novel hot-melt patch technology and is an upgraded version of Loxoprofen Sodium Cataplasms. It is thin and lightweight, comfortable to apply and has strong adhesion, and is indicated for the anti-inflammatory and analgesic treatment of the following diseases and symptoms: osteoarthritis, muscle pain, and swelling or pain caused by trauma. The originator product of Loxoprofen Sodium Patches (trade name: Loxonin) was approved for marketing in China in 2014. According to data from Menet, sales of Loxoprofen Sodium Patches in China’s three (3) major terminal markets amounted to approximately RMB920 million in 2025, and the market continues to grow rapidly.

洛索洛芬钠贴剂采用新型热熔贴剂技术，是洛索洛芬钠凝胶贴膏的升级产品，具有轻薄、贴敷舒适、黏附性强等特点，用于下述疾病及症状的消炎和镇痛：骨关节炎、肌肉痛、外伤导致的肿胀或疼痛。洛索洛芬钠贴剂原研产品（商品名：乐松）2014 年在国内获批上市。根据米内网数据，2025 年洛索洛芬钠贴剂在中国三大终端市场销售额约 9.2 亿元，当前仍处于高速增长阶段。

The marketing approval of the Drug represents another key milestone in the Company’s strategic development in the field of transdermal drug delivery. It demonstrates that the Company has

established end-to-end capabilities in the research and development, production and quality control of modern patch formulations, including cataplasms and hot-melt patches. Going forward, the Company intends to leverage its clinical experience in traditional Chinese medicine in the musculoskeletal field, together with the technical advantages of transdermal drug delivery formulations, to continue developing its modern patch product portfolio covering chemical drugs, traditional Chinese medicine and healthcare products.

洛索洛芬钠贴剂的获批上市，是公司在经皮给药领域战略布局取得的又一关键性成果，标志着公司具备以凝胶贴膏、热熔贴剂为代表的现代贴剂“研发-生产-质控”全流程能力，未来将依托在肌肉-骨骼系统领域的中药临床积淀，借力经皮给药制剂的技术优势，持续构建覆盖“化药-中药-健康品”的现代贴剂产品矩阵。

Leveraging the strengths of its century-old heritage brand, the Company will continue, as a leading enterprise in the field of modern traditional Chinese medicine, to develop new formulations and products with the aim of providing patients with better medication options and supporting the high-quality growth of its business.

公司将继续依托百年老字号品牌优势，作为现代中药引领者将持续在新型制剂、新产品研发上为患者提供更优质的用药选择，为业绩高质量发展注入新动能。